Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Recruiting · Phase 2 · NCT05997017
Conditions: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
At a glance
- Research payments reported, 2025
- $9.3M
- U.S. investigators named
- 8
- Sites paid
- 9
- Planned or actual enrollment
- 29
About the trial
- Sponsor
- Aadi Bioscience, Inc.
- Tested
- nab-sirolimus (drug)
- Dates
- Started 2023-12-28; completion 2027-06
- Results posted
- Not yet
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
From ClinicalTrials.gov, last updated 2025-11-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Aadi Bioscience, Inc. reported $9.3M in research payments for this study in 2025 (739 payments).
Products named: Fyarro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael J. Birrer, M.D. PH.D. Hematology & Oncology · Birmingham, AL
- Brian M. Slomovitz, M.D. Gynecologic Oncology · Fort Lauderdale, FL
- Allison M. Puechl, MD OB-GYN (Obstetrics & Gynecology) · Charlotte, NC
- Angela Green, MD Medical Oncology · New York, NY
- Lauren E. Dockery, M.D. Gynecologic Oncology · Oklahoma City, OK
- Cara A. Mathews, MD OB-GYN (Obstetrics & Gynecology) · Providence, RI
- Anna M. Priebe, M.D. Gynecologic Oncology · Tyler, TX
- Fernanda Musa, M.D. Gynecologic Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Cancer Center $4.9M
- Swedish Issaquah, WA $1.5M
- Mount Sinai Medical Center of Florida, Inc, FL $1.5M
- Board of Regents of the University of Oklahoma Health Sciences Center $618,857
- Wake Forest University Health Sciences $503,536
- Texas Oncology P.a. $284,495
- Texas Oncology, P.a. $44,051
- University of Arkansas Medical Sciences, AR $34,674
- Women & Infants Hospital of Rhode Island, RI $14,020
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.